All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-12-12T17:25:51.000Z

When should MRD status be used in clinical decision making in MM?

By Alia Mohamed, Elisabet Manasanch
Featured
Elisabet Manasanch
Dec 12, 2019
Share:

Bookmark this article

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Elisabet E. Manasanch, MD Anderson Cancer Center, Houston, US, answers the question: When should we test for minimal residual disease in clinical practice of multiple myeloma?

Elisabet Manasanch discusses the use of minimal residual disease (MRD) status to guide patient treatment choices, she explains MRD is currently being used to evaluate patient response and to monitor relapse.

When should we test for minimal residual in clinical practice of multiple myeloma?

More about...
ASHASH 2019Newly diagnosed multiple myelomaRelapsed/refractory multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
17 votes - 12 days left ...

Related articles

Add bookmark

Efficacy of autologous stem cell transplantation in patients aged ≥ 70 years with multiple myeloma

The impact of older age at transplant and its effect on post-transplant outcomes

Feb 13, 2020
Add bookmark

Efficacy of autologous stem cell transplantation in patients aged ≥ 70 years with multiple myeloma

The impact of older age at transplant and its effect on post-transplant outcomes

Feb 13, 2020
Add bookmark

How significant is the role of MRD status in MM, and how can we best utilize this information?

At ASH 2019, Bruno Paiva, University of Navarra, Pamplona, ES, answers the question: How significant is the role of minimal residual disease status in...

Dec 13, 2019
Add bookmark

How significant is the role of MRD status in MM, and how can we best utilize this information?

At ASH 2019, Bruno Paiva, University of Navarra, Pamplona, ES, answers the question: How significant is...

Dec 13, 2019

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox